Neovasc Reveals Positive Results For Reducer System Treatment For Refractory Angina Published In Cardiology Journal

Neovasc Inc. NVCN revealed Monday about the positive results of a single center, retrospective study using the Reducer product were published in the June 14, 2016 issue of The Netherlands Heart Journal in an article titled "Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single center real world experience".

According to Neovasc, the paper documented the results from 23 straight patients who were implanted with the Reducer to treat their severe refractory angina. The published results demonstrated that in all 23 patients, the Reducer device was implanted in a day hospital successfully setting without any adverse events.

The company indicated that following a median follow-up of 9 months (range 8 – 14 months) it was found that 17 of 23 patients showed at least one class improvement in their Canadian Cardiovascular Society (CCS) angina score: 8 patients (34.8%) improved by 1 CCS class, 7 (30.4%) by 2 CCS classes and 2 (8.7%) by 3 CCS classes.

Its Interventional Cardiologist and Senior Author of the trial, Pierfrancesco Agostoni, said, "Despite the large range of available anti-ischaemic medical therapies and revascularization techniques, a considerable number of patients still suffer from angina which is refractory to medical treatment. The results from this real world cohort, albeit from one centre and a relatively small sample size, are consistent with previous studies using Reducer such as COSIRA and found Reducer implantation to be safe and efficacious, with the majority of patients demonstrating significant improvement in angina symptoms following treatment."

The study involved a 400 patient, 40 sites, post market, multi-center, multi-country three-arm, five-year follow-up trial. Its primary endpoint was the percentage of subjects who experience improvement in their angina symptoms defined as a reduction in CCS grade at 6 months as compared to baseline. This trial was planned to offer further clinical proof supporting the use of the Reducer in this patient population.

In pre-market trading on Monday, the stock surged 25.5 percent.